Study protocol of the LARK (TROG 17.03) clinical trial: a phase II trial investigating the dosimetric impact of Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring
Yoo Young Dominique Lee, Trang Nguyen Doan, Trevor Moodie, Ricky O'Brien, Anne McMaster, Andrew Hickey, Nicole Pritchard, Per Poulsen, Elizaveta Mitkina Tabaksblat, Britta Weber, Esben Worm, David Pryor, Julie Chu, Nicholas Hardcastle, Jeremy Booth, Val Gebski, Tim Wang, Paul Keall
BMC CANCER | BMC | Published : 2021
BACKGROUND: Stereotactic Ablative Body Radiotherapy (SABR) is a non-invasive treatment which allows delivery of an ablative radiation dose with high accuracy and precision. SABR is an established treatment for both primary and secondary liver malignancies, and technological advances have improved its efficacy and safety. Respiratory motion management to reduce tumour motion and image guidance to achieve targeting accuracy are crucial elements of liver SABR. This phase II multi-institutional TROG 17.03 study, Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring (LARK), aims to investigate and assess the dosimetric impact of the KIM real-time image guidance technology. KIM ut..View full abstract
This trial is funded by the Australian Government Cancer Australia awarded to PK following a peer-review process. The funding body has no role in collecting, analysing or interpreting of the trial data.